Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.4 EUR | +1.29% | +1.08% | +33.14% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- With a P/E ratio at 11.16 for the current year and 9.44 for next year, earnings multiples are highly attractive compared with competitors.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company has a low valuation given the cash flows generated by its activity.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company does not generate enough profits, which is an alarming weak point.
- The company is in debt and has limited leeway for investment
- Revenue estimates are regularly revised downwards for the current and coming years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.14% | 228M | C+ | ||
+24.66% | 88.38B | C+ | ||
-21.76% | 77.56B | B- | ||
+8.45% | 26.97B | C+ | ||
+7.94% | 18.45B | A- | ||
-13.50% | 16.57B | B | ||
+77.51% | 13.65B | C- | ||
+76.96% | 13.06B | C+ | ||
+4.72% | 12.61B | A- | ||
+36.67% | 12.56B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PIHLIS Stock
- Ratings Pihlajalinna Oyj